

# You're looking at the answer to your recruitment problems!



It's the *Journal of the American Board of Family Practice*.  
Where you reach the best job candidates. More of them.  
More often. To find out more, just contact Classified  
Advertising at (617) 893-3800.



**The Journal of the American Board of  
Family Practice**

# CLASSIFIED ADVERTISING

Classified advertising orders, correspondence and payments should be directed to: *JABFP*, Classified Advertising, 1440 Main Street, Waltham, MA 02154.

Classified advertisements placed with *JABFP* are restricted to physician recruitment, faculty positions, CME courses/seminars, and practices for sale. All ads must relate to the medical field and are subject to approval.

Please refer to the schedule below for closing dates. Classified rate is \$1.40 per word (minimum charge of \$75.00 per ad insertion) and \$95.00 per column inch for classified display ads. Prepayment in full is required with all classified advertising. We accept American Express, VISA, or MasterCard. Confidential reply boxes are an additional \$10.00 per insertion. Responses are sent directly every Tuesday and Thursday and the box will remain open for three months.

All advertisements for employment must be nondiscriminatory and comply with all applicable laws and regulations. Ads that discriminate against applicants based on sex, age, race, religion, marital status or physical handicap will not be accepted.

**NOTE:** Our classified advertisements are all set in the same typeface and format. All ads are highlighted by geographic territory.

For more information please call (800) 635-6991 (outside MA), (617) 893-3800 (in MA). Fax # (617) 893-5003.

<i>Issue Date</i>	<i>Closing Date</i>	<i>Issue Date</i>	<i>Closing Date</i>
November-December	October 1, 1993	January-February	December 1, 1993
March-April	February 1, 1994	May-June	April 1, 1994

## MIDWEST

**COLUMBUS, OHIO — WANTED:** — Full-time faculty member for Family Practice Residency at Riverside Methodist Hospitals in Columbus, Ohio. OB skills required. Practice experience preferred. Competitive salary and excellent benefits. Nationally renowned institution in thriving city. Contact Ed Bope, MD or Bill Gegas, MD at: RIVERSIDE FAMILY PRACTICE, 797 Thomas Lane, Columbus, Ohio 43214, (614) 566-4398.

## NORTHEAST

**NEW ENGLAND** — Live in most beautiful region of the country and leave big city hassles. Easy commute to city life. Assume an immediate patient load of 1500-2000 patients and help build a family practice department your way. Exceptional Salary, benefits and sign-on bonus incentives. Excellent call schedule. This is a wonderful place to raise your children and enjoy skiing, Tanglewood concerts, Broadway summer theatre and more. Ann Breitner, Breitner, Clark and Hall 800-858-4225.

**NEW ENGLAND** — Booming area near Boston seeks FP who does OB. Strong Fp department and support from the hospital. Young families moving to the area. Hospital boasts 85% occupancy rate. Great place to raise your kids. Close to city, beaches and skiing. Excellent compensation structure. Ann Breitner, Breitner, Clark and Hall. 800-858-4225.

**NEW ENGLAND** — Massachusetts Oceanside 400-bed hospital is expanding Fp department. Join the hospital staff or choose a group practice. Hospital has enjoyed financial success. Excellent salary and benefits. Beautiful estate homes at reasonable prices. Commuting distance to Cape Cod, Boston and Providence. Ann Breitner, Breitner, Clark and Hall, 800-858-4225.

**CONNECTICUT SHORELINE** — Well-established urgent care center in Fairfield County seeks physician with strong clinical and leadership capabilities. Direct well-trained staff and enjoy the professional challenge of treating a wide variety of cases from sore throats to minor surgery. Center is owned by a major teaching hospital affiliated with Yale and New York Medical Colleges. NO CALL Salary and bonuses can exceed \$130,000. Mike Lane, 1-800-858-4225. Breitner, Clark & Hall, Inc.

**NEW HAMPSHIRE — FAMILY PRACTICE:** — Opportunity is available with the affiliated practices of Monadnock Community Hospital in Peterborough, NH. These satellite FP offices handle the primary care and non-urgent care needs of the area. Continuity of care is an essential part of these practices. Weekday office hours. Located

in the beautiful Southern Tier of New Hampshire — quaint New England villages and picturesque landscape. Area offers a slow paced lifestyle with easy access to the larger metro area of Boston (80 miles). For additional information, contact Denise Johnson, Spectrum Emergency Care, 1-800-325-3982, ext. 3017.

**MASSACHUSETTS — CAPE COD** — Where will you be in 2001? Enthusiastic BC/BE FP needed to join optimistic BC FP in beautiful Cape Cod community. Modern, spacious office. Income guarantee of \$85,000. Reply with CV to Floyd McIntyre, M.D., 76 Airline, South Dennis, MA 02660.

## PACIFIC

**FAMILY PRACTICE — PRACTICE OPPORTUNITY KNOCKS** — Outstanding group, clinic, solo Family Practice opportunities throughout California. Excellent compensation. Reply: SEARCH, P.O. Box 2224, Carlsbad, California 92018, 619-438-5900.

**WASHINGTON — FAMILY PRACTITIONERS** — wanted for creation of a Non-obstetrical Family Practice Department. Prominent, 100-physician, multi-specialty clinic with a significant interest in expanding primary care. Ideal opportunity to contribute new creative ideas in an interesting environment. Guaranteed salary and partnership track available. Excellent benefit package. Abundant four-season recreational opportunities in family-oriented community. Send C.V. to William Danke, M.D., P.O. Box 489, Wenatchee, WA 98807.

**FAMILY PRACTICE** — Premier multispecialty group near Portland, Oregon has two excellent opportunities for BC/BE family practitioners. Join one of two satellite clinics in which FPs and PAs currently practice. Superb lifestyle, abundant recreational opportunities, and generous benefits package. Send CV to: Karen Stanton, c/o The Vancouver Clinic, 700 NE 87th Ave., Vancouver, WA 98664.

## SOUTHEAST

**FAMILY PRACTICE** — Recruiting a socially conscious Family Practitioner, B.C. or B.E., for (semi-rural) Family Practice which is an educational site for health professional students. Current staff of 1 M.D., 1 P.A., and part-time N.P., needs another full-time physician. Includes hospital, office, and home visits. No OB. Looking for someone who is interested in personalized patient care, and community health education. Full benefit package including malpractice, CME, health benefits, competitive earning/salary compatible with comfortable middle class existence. Contact or send resume to Joseph I. Golden, M.D., Polk and Main Street, P.O. Box 1304, Sophia, WV 25921. (304) 683-4304.

# Start Your Practice with a Successful Operation

The Fallon Clinic is one of the country's most successful health care organizations, and we are looking for a **FAMILY PHYSICIAN** like YOU.

In addition to our ideal New England location, we offer you

- ◆ attractive salary and benefits package
- ◆ security of an established patient base
- ◆ excellent primary care and medical specialty support services
- ◆ administrative and clerical support staff
- ◆ academic opportunities
- ◆ research opportunities
- ◆ a promising, growth-oriented future
- ◆ time for yourself

And after two years, we offer you an equal share in this physician-owned and directed multispecialty group.

Why not call Medical Staff Development today at 1-800-635-1221, Ext. 2274.

Fallon Clinic. The perfect place to start...the perfect place to stay.

## *The Fallon Clinic*

100 Central Street, Worcester, MA 01608  
(800) 635-1221, Ext. 2274  
FAX 508-793-0909

*Please visit us at Booth # 839 at the  
AAFP Scientific Assembly*

# WHEN YOU CAN'T BREATHE,



# NOTHING ELSE MATTERS.™

Help the  
American Lung  
Association  
fight lung disease.

**+** AMERICAN  
LUNG  
ASSOCIATION.™


Space contributed by the publisher as a public service.

# Are you prepared to deal with the medical/legal complexities of modern health care?

It would be difficult to find a better guide to this complicated and controversial topic than William J. Curran's, *Law-Medicine Notes: Progress in Medicolegal Relations*.

As one of the nation's foremost medico-legal authorities, he has been instrumental in shaping almost every medical/legal issue of the last twenty-five years, from the right to die to standards for committing mental patients.

Now, in this annotated collection of essays drawn from his column in the *New England Journal of Medicine*, Curran gives us a unique opportunity to explore the complexities of the medical/legal relationship.



***Law-Medicine Notes: Progress in Medicolegal Relations***  
William J. Curran

*Collected and annotated, with a preface by Arnold S. Relman, M.D., and an Introduction by the author. 450 pages. Softcover. \$38.50.*

**Chapter 1: Medical malpractice** Good Samaritan laws... peer-review programs... informed consent... clinical experimentation... diagnostic errors.

**Chapter 2: Hospitals: the new legal doctrines** Liability for quality of care... malpractice arbitration... conditional medical treatment... cost-containment.

**Chapter 3: Forensic medicine and the law** Scientific evidence and the courts... damage suits... personal-injury law and lawyers... mass disasters.

**Chapter 4: Insanity, psychiatry, and the armor of the law** Proof of mental illness for

commitment... confidentiality in psychiatric practice... competency of the mentally retarded.

**Chapter 5: Ethics in medical practice** Compulsory drug testing... confidentiality in epidemiologic investigations... care for the dying... the patient's bill of rights.

**Chapter 6: Legal/moral problems in human reproduction** Birth control and privacy... abortion... sterilization of the poor... fetal research... the thalidomide tragedy.

**Chapter 7: Life and death** The uniform anatomical gift act... brain death... legal and medical death... brain death... the right to die.

Please send me \_\_\_\_\_ copies of William J. Curran's, ***Law-Medicine Notes: Progress in Medicolegal Relations***.

\$38.50 each (Massachusetts residents add 5% sales tax.) \_\_\_\_\_  
Plus \$2.50 postage and handling per copy \_\_\_\_\_

Enclosed is my check for: \_\_\_\_\_

*Make checks payable to the New England Journal of Medicine.*

Charge my: \_\_\_\_\_ VISA \_\_\_\_\_ MasterCard  
\_\_\_\_\_ American Express

Signature \_\_\_\_\_

Card Number \_\_\_\_\_ Exp Date \_\_\_\_\_

Name \_\_\_\_\_

Specialty \_\_\_\_\_

Organization \_\_\_\_\_

Address \_\_\_\_\_


City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Send to: **The New England Journal of Medicine**, P.O. Box 9130,  
Waltham, MA 02254-9130 To order by phone: (617) 893-3800  
ext. 1259 (Inside MA) 1-800-843-6356 (Outside MA).

*Allow four to six weeks for delivery.*

SBV01

# From the publisher of the first clinical studies on



## Comes the latest reprint collection on this important topic.


In the coming years, you and thousands of physicians like you will be providing—often for the first time—primary care for AIDS patients.

**AIDS: Epidemiologic and Clinical Studies, Volume II** can help you diagnose, evaluate and treat these patients.

This second volume in the Reprint Collection Series includes 63 original articles, published from February 1987 to February 1989, in *The New England Journal of Medicine*. These articles, along with editorial, correspondence and critical responses from practitioners in the field, provide a unique perspective for clinical understanding of Acquired Immunodeficiency Syndrome, its cause, characteristics, treatment, and public health implications.

Articles of particular interest:

- A study of the prevalence of HIV in teenagers and young adults.
- Evaluation of the extent of symptomatic HIV infection in adults presenting to an inner-city hospital for emergency treatment.
- New retrovirus, HIV-2, and the need for seroepidemiologic surveillance.
- Methods of diagnosing opportunistic infections.
- Clinical therapy trials of the drug azidothymidine (AZT).



**TO ORDER CALL TOLL FREE  
1-800-THE-NEJM**

In MA, CALL  
617-893-3800, ext. 1199



**The New England  
Journal of Medicine**

Please send me \_\_\_\_\_ copies of  
**AIDS: Epidemiologic and Clinical Studies,  
Volume II.**

Hardcover, 440 pages, ISBN 0-910133-29-8 for \$45.00\* + \$3.50 postage and handling per copy.

Paperbound, 440 pages, ISBN 0-910133-25-5 for \$35.00\* + \$2.75 postage and handling per copy.

Here is my check for: \$ \_\_\_\_\_

Please charge in the amount of \$ \_\_\_\_\_

VISA     AmEx     MasterCard

CARD # \_\_\_\_\_ EXP. DATE \_\_\_\_\_

SIGNATURE \_\_\_\_\_

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_

STATE \_\_\_\_\_ ZIP \_\_\_\_\_

\* Mass. residents please add 5% sales tax.

All orders must be prepaid. Make checks payable to  
**The New England Journal of Medicine.** Send to:  
The New England Journal of Medicine, Box 9130,  
Waltham, MA 02254-9130, FAX: 617-893-0413

# Sectral<sup>®</sup> 200 mg 400 mg CAPSULES

## acebutolol HCl

The Only Cardioselective Beta Blocker  
Indicated for PVC Control

<b>Usual starting dose</b>	200 mg BID
<b>Optimal PVC response</b>	600 mg to 1200 mg per day
<b>Use in elderly</b>	400 mg to 800 mg per day  Doses above 800 mg per day should be avoided

### (SECTRAL - Brief Summary of prescribing information.)

**CONTRAINDICATIONS:** SECTRAL is contraindicated in: 1) persistently severe bradycardia; 2) second- and third-degree heart block; 3) overt cardiac failure; 4) cardiogenic shock. (See WARNINGS)

**WARNINGS: Cardiac Failure:** Sympathetic stimulation may be essential for support of circulation in patients with diminished myocardial contractility, and inhibition by  $\beta$ -adrenergic receptor blockade may precipitate more severe failure. Although  $\beta$ -blockers should be avoided in overt cardiac failure, SECTRAL can be used cautiously when heart failure is controlled with digitalis and/or diuretics. Digitalis and SECTRAL impair AV conduction. Withdraw SECTRAL if cardiac failure persists.

**In Patients Without a History of Cardiac Failure:** In patients with aortic or mitral valve disease or compromised left ventricular function, continued depression of the myocardium with  $\beta$ -blockers over time may lead to cardiac failure. Digitalize patients at first signs of failure, and/or give a diuretic and observe closely. Withdraw SECTRAL if cardiac failure persists.

**Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal:** Abrupt discontinuation of some  $\beta$ -blockers in coronary artery disease patients may exacerbate angina; in some cases, myocardial infarction and death have been reported. Caution such patients against interruption of therapy without a physician's advice. Even in the absence of overt ischemic heart disease, withdraw SECTRAL gradually over a period of about two weeks; observe carefully and advise patients to minimize physical activity during this time. (If desired, patients may be transferred directly to comparable doses of an alternative  $\beta$ -blocker without interruption of  $\beta$ -blocking therapy). If exacerbation of angina occurs, restart full-dose anti-anginal therapy immediately and hospitalize patient until stabilized.

**Peripheral Vascular Disease:**  $\beta$ -antagonists reduce cardiac output and can precipitate/aggravate arterial insufficiency in patients with peripheral or mesenteric vascular disease. Exercise caution and observe such patients closely for progression of arterial obstruction.

**Bronchospastic Diseases: Patients with Bronchospastic Disease Should, in General, Not Receive a  $\beta$ -Blocker.** Because of its relative  $\beta_1$ -selectivity, low doses of SECTRAL may be used cautiously in such patients who do not respond to, or cannot tolerate, alternative treatment.

Since  $\beta_1$ -selectivity is not absolute and is dose-dependent, use lowest possible dose of SECTRAL initially, preferably in divided doses. Make bronchodilator, e.g., theophylline, or a  $\beta_2$ -stimulant, available in advance with instructions for use.

**Anesthesia and Major Surgery:** The necessity/desirability of withdrawing  $\beta$ -blockers prior to major surgery is controversial; the heart's impaired ability to respond to  $\beta$ -adrenergically mediated reflex stimuli may enhance the risk of excessive myocardial depression during general anesthesia. Difficulty in restarting and maintaining the heartbeat also has been reported with beta-blockers. If treatment is continued, take special care when using anesthetics that depress the myocardium; use lowest possible SECTRAL dose. SECTRAL, like other  $\beta$ -blockers, is a competitive inhibitor of  $\beta$ -receptor agonists, so its effects can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol). Symptoms of excessive vagal tone (e.g., profound bradycardia, hypotension) may be corrected with atropine.

**Diabetes and Hypoglycemia:**  $\beta$ -blockers may potentiate insulin-induced hypoglycemia and mask some symptoms such as tachycardia; dizziness and sweating are usually not significantly affected. Warn diabetics of possible masked hypoglycemia.

**Thyrotoxicosis:**  $\beta$ -adrenergic blockade may mask some clinical signs (tachycardia) of hyperthyroidism. Abrupt withdrawal of SECTRAL may precipitate a thyroid storm in patients suspected of developing thyrotoxicosis.

**PRECAUTIONS: Impaired Renal or Hepatic Function:** While there are no U.S. studies, foreign published experience shows that acebutolol has been used successfully in chronic renal insufficiency. Acebutolol is excreted via the G.I. tract, but the active metabolite, diacetolol, is eliminated mainly by the kidney. A linear relationship exists between renal clearance of diacetolol and creatinine clearance ( $Cl_{cr}$ ); reduce daily dose of acebutolol by 50% when  $Cl_{cr}$  is less than 50 mL/min and by 75% when it is less than 25 mL/min. Use cautiously in patients with impaired hepatic function.

SECTRAL has been used successfully and without problems in elderly patients in U.S. clinical trials without specific dosage adjustment. However, in the elderly, lower maintenance doses may be required because bioavailability of SECTRAL and its metabolite are approximately doubled.

**Information for Patients:** Warn patients, especially those with evidence of coronary artery disease, against interruption or discontinuation of SECTRAL without physician supervision. Although cardiac failure rarely occurs in properly selected patients, advise patients to consult a physician if signs or symptoms suggestive of impending CHF, or unexplained respiratory symptoms, develop.

Warn patients of possible severe hypertensive reactions from concomitant use of  $\alpha$ -adrenergic stimulants, e.g., nasal decongestants used in OTC cold medicines and nasal drops.

**Clinical Laboratory Findings:** SECTRAL, like other  $\beta$ -blockers, has been associated with development of antinuclear antibodies (ANA). In prospective clinical trials, patients receiving SECTRAL had a dose-dependent increase in the development of positive ANA titers. Symptoms related to this laboratory abnormality were infrequent. Symptoms and ANA titers were reversible upon discontinuation of SECTRAL.

**Drug Interactions:** Catecholamine-depleting drugs may have additive effects when given with  $\beta$ -blockers. Observe patients treated with both agents closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia. Exaggerated hypertensive responses have been reported from use of  $\beta$ -adrenergic antagonists with  $\alpha$ -adrenergic stimulants, including those in OTC cold remedies and vasoconstrictive nasal drops. Nonsteroidal anti-inflammatory drugs may blunt antihypertensive effects of beta-blockers.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Chronic oral toxicity studies in rats and mice, at doses 15 times the maximum recommended (60 kg) human dose, did not indicate carcinogenic potential for SECTRAL. Diacetolol, the major metabolite in man, was without carcinogenic potential in rats at doses up to 1800 mg/kg/d. SECTRAL and diacetolol also had no mutagenic potential in the Ames Test. No significant impact on reproductive performance or fertility was found in rats following SECTRAL or diacetolol doses of up to 240 or 1000 mg/kg/d, respectively.

**Pregnancy: Teratogenic Effects:** Pregnancy Category B: No teratogenic effects were seen in rat or rabbit reproduction studies utilizing SECTRAL doses that were, respectively, approximately 31.5 and 6.8 times the maximum recommended human dose. At this dose in the rabbit, slight fetal growth retardation was noted; this was considered to be a result of maternal toxicity (evidenced by reduced food intake, lowered rate of body weight gain, mortality). Diacetolol studies (doses up to 450 mg/kg/d in rabbits and up to 1800 mg/kg/d in rats) showed no evidence of fetal harm other than a significant elevation in postimplantation loss with 450 mg/kg/d, a level at which food consumption and body weight gain were reduced in rabbit dams; there was a nonstatistically significant increase in incidence of bilateral cataract in rat fetuses from dams treated with 1800 mg/kg/d. There are no adequate and well-controlled trials in pregnant women; SECTRAL should be used during pregnancy only if potential benefit justifies risk to the fetus.

**Nonteratogenic Effects:** Human studies indicate that acebutolol and diacetolol cross the placenta. Neonates of mothers who received acebutolol during pregnancy have reduced birth weight, decreased blood pressure, and decreased heart rate.

**Labor and Delivery:** Effect on labor and delivery in pregnant women is unknown. Animal studies have shown no effect of SECTRAL on the usual course of labor and delivery.

**Nursing Mothers:** Acebutolol and diacetolol appear in breast milk (milk:plasma ratio of 7.1 and 12.2, respectively). Use in nursing mothers is not recommended.

**Pediatric Use:** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS:** SECTRAL is well tolerated in properly selected patients.

Most adverse effects have been mild, not required therapy discontinuation, and tended to decrease as treatment duration increases.

The incidence of treatment-related side effects (volunteered and elicited) derived from U.S. controlled clinical trials in patients with hypertension, angina and arrhythmia follows. Numbers represent percentage incidence for SECTRAL (N=1002) versus placebo (N=314), respectively.

**Cardiovascular:** Chest pain 2%, 1%; Edema 2%, 1%. **CNS:** Depression 2%, 1%; Dizziness 6%, 2%; Fatigue 11%, 4%; Headache 6%, 4%; Insomnia 3%, 1%; Abnormal dreams 2%, 1%. **Dermatologic:** Rash 2%, 1%; **Gastrointestinal:** Constipation 4%, 0%; Diarrhea 4%, 1%; Dyspepsia 4%, 1%; Flatulence 3%, 1%; Nausea 4%, 0%. **Genitourinary:** Micturition (frequency) 3%, <1%. **Musculoskeletal:** Arthralgia 2%, 2%; Myalgia 2%, 0%. **Respiratory:** Cough 1%, 0%; Dyspnea 4%, 2%; Rhinitis 2%, <1%. **Special Senses:** Abnormal Vision 2%, 0%.

The following selected (potentially important) side effects were seen in up to 2% of SECTRAL patients: **Cardiovascular:** hypotension, bradycardia, heart failure. **CNS:** anxiety, hyper/hypoesthesia, impotence. **Skin:** pruritus. **Gastrointestinal:** vomiting, abdominal pain. **Genitourinary:** dysuria, nocturia. **Liver and Biliary:** small number of reported cases of liver abnormalities (increased SGOT, SGPT, LDH). In some cases, increased bilirubin or alkaline phosphatase, fever, malaise, dark urine, anorexia, nausea, headache, and/or other symptoms have been reported. In some cases, symptoms and signs were confirmed by rechallenge. Abnormalities were reversible upon drug cessation. **Musculoskeletal:** back and joint pain. **Respiratory:** pharyngitis, wheezing. **Special Senses:** conjunctivitis, dry eye, eye pain. **Autoimmune:** extremely rare reports of systemic lupus erythematosus.

Incidence of drug-related adverse effects (volunteered and solicited) based on SECTRAL dose is shown below. (Data from 266 hypertensive patients treated for 3 months on a constant dose.)

Body System	400 mg/day (N=132)	800 mg/day (N=63)	1200 mg/day (N=71)
Cardiovascular	5%	2%	1%
Gastrointestinal	3%	3%	7%
Musculoskeletal	2%	3%	4%
Central Nervous System	9%	13%	17%
Respiratory	1%	5%	6%
Skin	1%	2%	1%
Special Senses	2%	2%	6%
Genitourinary	2%	3%	1%

**Potential Adverse Effects:** Certain adverse effects not listed above have been reported with other  $\beta$ -blocking agents and should be considered as potential adverse effects of SECTRAL.

**CNS:** Reversible mental depression progressing to catatonia, an acute syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuro-psychometrics.

**Cardiovascular:** Intensification of AV block (see CONTRAINDICATIONS).

**Allergic:** Erythematous rash, fever with aching and sore throat, laryngospasm, respiratory distress.

**Hematologic:** Agranulocytosis, nonthrombocytopenic and thrombocytopenic purpura.

**Gastrointestinal:** Mesenteric arterial thrombosis, ischemic colitis.

**Miscellaneous:** Reversible alopecia, Peyronie's disease. The oculocutaneous syndrome associated with prazosin has not been reported with SECTRAL.

**Keep at room temperature. Approximately 25°C (77°F).**

3482-6 8/13/92

### Reference:

1. Data on file, Wyeth-Ayerst Laboratories.

**WYETH-AYERST**  
LABORATORIES  
Philadelphia, PA 19101

Printed in U.S.A.

21009R